Share Search
Visit the Share Search
Diaceutics secures multiple contracts with 'leading' pharma firms
24th Jun 2021 10:15
(Sharecast News) - Diagnostics commercialisation company Diaceutics has secured four contracts with two "leading pharmaceutical companies" to solve real-world testing hurdles for inherited retinal disease.
Diaceutics said on Thursday that the contracts, which demonstrates the applicability of its DXRX diagnostic commercialisation platform outside of its core area of oncology, will be delivered over the course of six months in 2021 across Europe, the UK, Asia-Pacific and the US.
The AIM-listed firm stated the projects were in partnership with existing pharmaceutical customers of the company and represented an expansion of its commercial relationship into a new therapy area, in line with its "land and expand" strategy.
Diaceutics also highlighted that contracts will deliver approximately £1.0m of revenues in 2021.
Chief executive Peter Keeling said: "These new project wins across a new disease area show the confidence that leading pharma companies have in Diaceutics and our considerable expansion opportunity.
"Through utilising the DXRX platform, alongside our advisory services, the projects can be delivered efficiently, at scale, across multiple geographies, bringing together all the segments in the precision medicine diagnostics market required to facilitate change and ensure patients get the right treatment at the right time."
As of 1015 BST, Diaceutics shares were up 0.63% at 128.80p.
Diaceutics said on Thursday that the contracts, which demonstrates the applicability of its DXRX diagnostic commercialisation platform outside of its core area of oncology, will be delivered over the course of six months in 2021 across Europe, the UK, Asia-Pacific and the US.
The AIM-listed firm stated the projects were in partnership with existing pharmaceutical customers of the company and represented an expansion of its commercial relationship into a new therapy area, in line with its "land and expand" strategy.
Diaceutics also highlighted that contracts will deliver approximately £1.0m of revenues in 2021.
Chief executive Peter Keeling said: "These new project wins across a new disease area show the confidence that leading pharma companies have in Diaceutics and our considerable expansion opportunity.
"Through utilising the DXRX platform, alongside our advisory services, the projects can be delivered efficiently, at scale, across multiple geographies, bringing together all the segments in the precision medicine diagnostics market required to facilitate change and ensure patients get the right treatment at the right time."
As of 1015 BST, Diaceutics shares were up 0.63% at 128.80p.